Recent Quotes (30 days)

You have no recent quotes
chg | %

Aurinia Pharmaceuticals Inc  

(Public, TSE:AUP)   Watch this stock  
Find more results for TSE:ISA
-0.05 (-0.76%)
Delayed:   10:12AM EST
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 6.47 - 6.61
52 week 2.75 - 14.17
Open 6.54
Vol / Avg. 8,173.00/67,390.00
Mkt cap 546.66M
P/E     -
Div/yield     -
EPS -1.67
Shares 83.97M
Beta 3.17
Inst. own     -
Nov 14, 2017
Q3 2017 Aurinia Pharmaceuticals Inc Earnings Call - Webcast
Oct 20, 2017
Aurinia Pharmaceuticals Inc. R&D Day - Webcast
Sep 27, 2017
Aurinia Pharmaceuticals Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Sep 26, 2017
Aurinia Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference
Sep 11, 2017
Aurinia Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -45241.38% -13465.32%
Operating margin -47551.72% -13187.28%
EBITD margin - -12332.37%
Return on average assets -25.82% -51.44%
Return on average equity -30.41% -83.33%
Employees 20 -
CDP Score - -


1203-4464 Markham St
+1-250-7084272 (Phone)
+1-250-7442498 (Fax)

Website links


Aurinia Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company's primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN. Voclosporin is an oral drug, administered twice daily. It is structurally similar to cyclosporine A (CsA), but is chemically modified on the amino acid-1 residue. It has completed two Phase III clinical studies in patients with moderate to severe psoriasis. It has completed Phase IIb clinical trial, which is a randomized, controlled, double-blind study comparing the efficacy of voclosporin as a component of multi-targeted therapy against placebo in achieving remission in patients with active LN.

Officers and directors

Richard M. Glickman LL.D. Executive Chairman of the Board, Chief Executive Officer
Age: 57
Dennis Bourgeault Chief Financial Officer, Corporate Secretary
Michael R. Martin Chief Operating Officer
Neil Solomons M.D. Chief Marketing Officer
Celia Economides Associate Vice President, Corporate Communications & Patient Advocacy
Robert B. Huizinga Vice President - Clinical Affairs
Lawrence D. Mandt Vice President - Regulatory and Quality
Age: 57
George M. Milne Jr., Ph.D. Director
Age: 73
Lorin Jeffry Randall Director
Age: 73
Benjamin Rovinski Ph.D. Independent Director
Age: 58